Crms Consulting Wins Export Award
Crms Consulting Wins Export Award - Recognition For Pharmaceutical Expertise
Auckland, February 14, 2003 -- CRMS Consulting Ltd, an Auckland company that helps international pharmaceutical companies improve their profitability through more effective use of their sales and marketing resources, has won a Trade New Zealand Export Award.
The award, part of the new Emerging Exporter section of the annual Trade New Zealand Export Awards, is in recognition of CRMS Consulting’s success in developing a viable and growing export business in three years.
(NB to Editors: Media are invited to attend the presentation of the CRMS Consulting Export Award by Trade New Zealand director Peter Menzies at 10am on 14 February 2003 at the company’s premises, Level 7, 182 Broadway, Newmarket, Auckland.)
CRMS Consultant Paul Millett says his consulting company works with senior sales and marketing executives in the pharmaceutical industry to improve their understanding of their customers, with a view to using this information to optimise utilisation of sales and marketing resources.
Mr Millett says CRMS’ consultants all have extensive experience in the international pharmaceutical industry. Using this knowledge the company has developed unique processes and software to help its clients.
“We aim to deliver measurable and rapid improvements to our clients’ sales and marketing effectiveness. We achieve this through a mix of strategic marketing consultancy, business analysis, training and internally-developed proprietary software solutions.
“We understand the pharmaceutical industry intimately. No other company is doing what we are doing with the same level of industry expertise. In addition, we have a cost effective infrastructure which gives us internationally competitive pricing.”
Mr Millett says while the company recently won a contract within the New Zealand pharmaceutical industry, as a result of its international success, the company was established in 1999 to focus on export.
“From the outset, the directors and founders of CRMS, David Ledger and Richard Clapp, developed the company with an international focus.
“Our main focus to date has been on Australia – it’s the closest viable pharmaceutical market to New Zealand. It is also small enough to develop and grow while avoiding detection from international competitors while we were becoming established.
“We have achieved record foreign exchange earnings in the past 12 months, the result of successfully completing several major projects with Australian pharmaceutical companies. “Relationships are critical to success in the pharmaceutical industry and networking is one of our most important marketing strategies. We have had an office and senior consultant permanently based in Sydney for the last two years to provide additional contact with clients.”
Mr Millet says over the past 12 months the company has also put a lot of work into defining its position in the market, its branding, and identifying where its most profitable niches and key strengths lie.
Trade New Zealand Account Manager Murray Jeffrey congratulated CRMS Consulting on its Export Award, saying the company’s initial focus on the Australian market has helped it gain international credibility.
“Focusing on one market has enabled CRMS Consulting to consolidate its positioning and services. It’s now completed several major contracts in Australia and will be able to leverage off these to target pharmaceutical clients in other markets.”
Paul Millett says CRMS Consulting is entering a new phase of growth and will be increasing its current staff resources of 16 to support this growth expansion.
“We are planning to open an office in the UK in 2003 as a stepping stone into the important European market. We will also continue to invest in developing new software tools and business processes to ensure that we retain our competitive advantage.
also recognised that there are opportunities to transfer our
expertise and processes to different industries beyond the
pharmaceutical sector and will explore this potential over
the next 12 months.”